Talquetamab-tgvs has received accelerated approval for relapsed or refractory multiple myeloma

The Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Share This Post

August 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) has been given accelerated approval by the Food and Drug Administration for the treatment of adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, including proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody.

A single-arm, open-label, multicenter research called MMY1001 (MonumenTAL-1) (NCT03399799, NCT4634552) that included 187 patients who had previously had at least four systemic medications assessed the efficacy of the treatment. Following two step-up doses in the first week of therapy, patients received talquetamab-tgvs 0.4 mg/kg subcutaneously weekly or talquetamab-tgvs 0.8 mg/kg subcutaneously biweekly (every two weeks), following three step-up doses, until disease progression or intolerable toxicity.

Overall response rate (ORR) and duration of response (DOR), which were evaluated by an independent review committee based on IMWG guidelines, were the primary efficacy outcome measures. Patients who had previously had at least four lines of therapy, such as a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody, made up the primary efficacy population. The median DOR was 9.5 months (95% CI: 6.5, not estimable) and the ORR in the 100 patients taking 0.4 mg/kg weekly was 73% (95% confidence interval (CI): 63.2%, 81.4%). The median DOR in the 87 patients taking 0.8 mg/kg biweekly was not estimable, while the ORR was 73.6% (95% CI: 63%, 82.4%). About 85% of respondents reportedly continued to respond for at least nine months.

A Boxed Warning for immunological effector cell-associated neurotoxicity (ICANS) and neurologic toxicity, including life-threatening or lethal cytokine release syndrome (CRS), is included in the prescribing material for talquetamab-tgvs. Talquetamab-tgvs is only offered in a restricted programme under a Risk Evaluation and Mitigation Strategy (REMS), known as the Tecvayli-Talvey REMS, due to the risks of CRS and neurologic toxicity, including ICANS.

The 339 patients in the safety population experienced CRS, dysgeusia, nail disorder, musculoskeletal discomfort, skin disorder, rash, exhaustion, loss of weight, dry mouth, pyrexia, xerosis, dysphagia, upper respiratory tract infection, diarrhoea, and adverse events in that order ( 20%).

Talquetamab-tgvs should be administered at a dose of either 0.4 mg/kg weekly or 0.8 mg/kg biweekly. The complete dose schedules are listed in the prescribing information.

View full prescribing information for Talvey

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy